Effect of topical tretinoin, chemical peeling and dermabrasion on p53 expression in facial skin.
The tumour suppressor protein p53 is a phosphoprotein that is activated by DNA damage. It is involved in the decision whether the cells should stop replication and proceed to repair their DNA, or to die by apoptosis. In the present study, we evaluate the effect of some treatment modalities on the expression of p53 in facial skin. Biopsy specimens were obtained from the facial skin of 20 patients before and after treatment using topical tretinoin (11 cases), TCA chemical peeling (5 cases) and dermabrasion (4 cases). Biopsy specimens were also obtained from 12 control subjects representing the same age groups of the patients. Topical tretinoin therapy was found to induce a significant decrease in the expression of p53 up to 6 months of therapy followed by a significant increase after 10 months of therapy. On the contrary, superficial TCA peeling did not induce any statistically significant change in the expression of p53. On the other hand dermabrasion was found to induce a significant decrease in the level of expression of p53 in biopsies obtained after complete re-epithelialization followed by a significant increase. These changes in the expression of p53 may play a role in mediating the effects of such treatment modalities on the epidermis, as well as prevention of actinic neoplasia by adjusting any disturbance in the proliferation/apoptosis balance observed in photoaged facial skin.
El-Domyati
Moetaz M
MM
Department of Dermatology, Faculty of Medicine, Al-Minya University, Cairo, Egypt. m_domyati@hotmail.com
Attia
Sameh K
SK
Saleh
Fatma Y
FY
Ahmad
Hesham M
HM
Gasparro
Frances P
FP
Uitto
Jouni J
JJ
D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D017209:Apoptosis; D002455:Cell Division; D002615:Chemexfoliation / Q000379:methods*; D003869:Dermabrasion / Q000379:methods*; D005145:Face; D005260:Female; D015870:Gene Expression; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D012867:Skin / Q000503:physiopathology; D015595:Skin Aging / Q000502:physiology; D014212:Tretinoin / Q000008:administration & dosage*; D016159:Tumor Suppressor Protein p53 / Q000096:biosynthesis / Q000235:genetics*
D000970:Antineoplastic Agents; D016159:Tumor Suppressor Protein p53; D014212:Tretinoin